d, "Initial indications point to strong comparative results between INVOcell and traditional in-vitro fertilization measures without any safety concerns. We look forward to finalizing the submission of this application to ANVISA with the goal of obtaining registration and approval for the sale the INVOcell device. As I originally stated, the treatment of couples with INVOcell is making the original purpose of the Human Reproductive Service of the Hospital School possible again by allowing universal access for infertile couples at a very reasonable cost. I remain excited to be at the leading edge in advancing the development of this breakthrough in reproductive medicine for the people of Brazil."
In Brazil, there are more than 125 fertility centers licensed to perform assisted reproductive procedures. According to the Brazilian Ministry of Health there are more than 15 million infertile couples in Brazil, with less than 1% of these couples actively seeking treatment. The many advantages of the INVOcell device and procedure include: the processing of significantly fewer eggs from patients, reducing the occurrence of multiple pregnancies and the attendant costs and complications; the relative cost advantages of the INVOcell procedure compared to traditional IVF treatments;pregnancy rates that are comparable to traditional IVF treatments.
INVOcell is CE Mark approved in Europe and Canada and conforms with all consumer health and safety requirements. INVOcell is currently marketed and sold in Austria, Bolivia, Cameroon, Columbia, the Dominican Republic, Guatemala, Nicaragua, Pakistan, Panama, Peru, Spain, Togo, Turkey, Poland, Spain, Switzerland, Greece, and Bulgaria. The company continues to market its products in all applicable countries covered by CE Mark or other local accepted criteria. Additionally, the company has commenced registration processes in Ukraine, China, Argentina, Venezuela, Russia aPage: 1 2 3 4 Related biology technology :1
. Avantra Biosciences Announces Significant Reduction In Multiplex Immunoassay Processing Time2
. Avantra Biosciences Announces the Launch of a Rapid Assay Prototyping Service3
. GeneLink Biosciences Expands its Scientific Advisory Board to Support New Product Lines4
. Ardea Biosciences to Present at Upcoming Investor Conferences5
. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Receives the Virginia Bioscience Company of the Year Award6
. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting7
. Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum8
. TEI Biosciences Wins SBANE 2011 New England Innovation Award9
. Transposagens piggyBac™ Vectors to be Distributed by System Biosciences10
. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results11
. Cell Biosciences Announces Issuance of Three US Patents